Novolog Pharm-Up 1966 Ltd
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Health Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation proces… Read more
Novolog Pharm-Up 1966 Ltd (NVLG) - Total Liabilities
Latest total liabilities as of September 2025: ILA2.68 Billion ILA
Based on the latest financial reports, Novolog Pharm-Up 1966 Ltd (NVLG) has total liabilities worth ILA2.68 Billion ILA as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Novolog Pharm-Up 1966 Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Novolog Pharm-Up 1966 Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Novolog Pharm-Up 1966 Ltd Competitors by Total Liabilities
The table below lists competitors of Novolog Pharm-Up 1966 Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Correlate Infrastructure Partners Inc
OTCQB:CIPI
|
USA | $9.91 Million |
|
Modern Healthcare Technology Holdings Limited
F:M3L
|
Germany | €362.05 Million |
|
Carmat SA
F:CXT
|
Germany | €93.56 Million |
|
Urban-Gro Inc
NASDAQ:UGRO
|
USA | $42.08 Million |
|
Coca Cola HBC AG
LSE:CCH
|
UK | GBX7.67 Billion |
|
Star Navigation Systems Group Ltd
PINK:SNAVF
|
USA | $6.59 Million |
|
Carmel Corp Ltd.
TA:CRML
|
Israel | ILA500.51 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Novolog Pharm-Up 1966 Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novolog Pharm-Up 1966 Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novolog Pharm-Up 1966 Ltd (2014–2024)
The table below shows the annual total liabilities of Novolog Pharm-Up 1966 Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA2.65 Billion | +10.97% |
| 2023-12-31 | ILA2.39 Billion | +21.29% |
| 2022-12-31 | ILA1.97 Billion | +6.15% |
| 2021-12-31 | ILA1.86 Billion | -1.73% |
| 2020-12-31 | ILA1.89 Billion | +0.23% |
| 2019-12-31 | ILA1.89 Billion | +15.70% |
| 2018-12-31 | ILA1.63 Billion | -5.22% |
| 2017-12-31 | ILA1.72 Billion | +18.42% |
| 2016-12-31 | ILA1.45 Billion | -5.48% |
| 2015-12-31 | ILA1.54 Billion | +24.78% |
| 2014-12-31 | ILA1.23 Billion | -- |